JP3961948B2 - テトラゾリル−フェニルアセトアミドであるグルコキナーゼ活性化物質 - Google Patents

テトラゾリル−フェニルアセトアミドであるグルコキナーゼ活性化物質 Download PDF

Info

Publication number
JP3961948B2
JP3961948B2 JP2002519452A JP2002519452A JP3961948B2 JP 3961948 B2 JP3961948 B2 JP 3961948B2 JP 2002519452 A JP2002519452 A JP 2002519452A JP 2002519452 A JP2002519452 A JP 2002519452A JP 3961948 B2 JP3961948 B2 JP 3961948B2
Authority
JP
Japan
Prior art keywords
mmol
reaction mixture
phenyl
methyl
cyclopentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002519452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004506632A5 (US07981874-20110719-C00313.png
JP2004506632A (ja
Inventor
シドゥリ，アチュサラオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004506632A publication Critical patent/JP2004506632A/ja
Publication of JP2004506632A5 publication Critical patent/JP2004506632A5/ja
Application granted granted Critical
Publication of JP3961948B2 publication Critical patent/JP3961948B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002519452A 2000-08-15 2001-08-09 テトラゾリル−フェニルアセトアミドであるグルコキナーゼ活性化物質 Expired - Fee Related JP3961948B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15
PCT/EP2001/009207 WO2002014312A1 (en) 2000-08-15 2001-08-09 Tetrazolyl-phenyl acetamide glucokinase activators

Publications (3)

Publication Number Publication Date
JP2004506632A JP2004506632A (ja) 2004-03-04
JP2004506632A5 JP2004506632A5 (US07981874-20110719-C00313.png) 2005-03-17
JP3961948B2 true JP3961948B2 (ja) 2007-08-22

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002519452A Expired - Fee Related JP3961948B2 (ja) 2000-08-15 2001-08-09 テトラゾリル−フェニルアセトアミドであるグルコキナーゼ活性化物質

Country Status (20)

Country Link
US (3) US6369232B1 (US07981874-20110719-C00313.png)
EP (1) EP1311504B1 (US07981874-20110719-C00313.png)
JP (1) JP3961948B2 (US07981874-20110719-C00313.png)
KR (1) KR100518061B1 (US07981874-20110719-C00313.png)
CN (1) CN1209362C (US07981874-20110719-C00313.png)
AR (1) AR031718A1 (US07981874-20110719-C00313.png)
AT (1) ATE297921T1 (US07981874-20110719-C00313.png)
AU (2) AU8399801A (US07981874-20110719-C00313.png)
BR (1) BR0113312A (US07981874-20110719-C00313.png)
CA (1) CA2419416C (US07981874-20110719-C00313.png)
DE (1) DE60111540T2 (US07981874-20110719-C00313.png)
DK (1) DK1311504T3 (US07981874-20110719-C00313.png)
ES (1) ES2243541T3 (US07981874-20110719-C00313.png)
MX (1) MXPA03001275A (US07981874-20110719-C00313.png)
PA (1) PA8525201A1 (US07981874-20110719-C00313.png)
PE (1) PE20020386A1 (US07981874-20110719-C00313.png)
PT (1) PT1311504E (US07981874-20110719-C00313.png)
UY (1) UY26885A1 (US07981874-20110719-C00313.png)
WO (1) WO2002014312A1 (US07981874-20110719-C00313.png)
ZA (1) ZA200300904B (US07981874-20110719-C00313.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918363B (zh) * 2008-01-18 2012-09-05 安斯泰来制药株式会社 苯乙酰胺衍生物

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
CA2498089A1 (en) * 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
MXPA06011365A (es) 2004-04-02 2006-12-15 Novartis Ag Derivados de tiazolo-piridina, composiciones farmaceuticas que los contienen, y metodos para el tratamiento de condiciones mediadas por glucoquinasa.
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
CN101218237B (zh) 2005-07-11 2012-03-28 田边三菱制药株式会社 肟衍生物及其制备方法
BRPI0615236A2 (pt) 2005-08-31 2011-05-10 Astellas Pharma Inc derivado de tiazol
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
KR20080048504A (ko) 2005-09-29 2008-06-02 사노피-아벤티스 페닐- 및 피리디닐-1,2,4-옥사디아졸론 유도체, 이의제조방법 및 약제로서의 이의 용도
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
BRPI0619980A2 (pt) * 2005-12-15 2014-10-14 Nihon Nohyaku Co Ltd Derivados de ftalamida e de anilina, inseticida agrícola ou hortícula, e, método de uso do mesmo
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
ATE522518T1 (de) * 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8314247B2 (en) * 2007-01-10 2012-11-20 Mitsubishi Tanabe Pharma Corporation Hydrazone derivative
JP5248477B2 (ja) 2007-03-07 2013-07-31 杏林製薬株式会社 グルコキナーゼ活性化物質
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
JP5580201B2 (ja) * 2007-10-08 2014-08-27 アドビヌス・セラピューティクス・プライベート・リミテッド グルコキナーゼアクチベータとしてのアセトアミド誘導体、その製法及び医薬応用
TW200934772A (en) * 2008-01-15 2009-08-16 Lilly Co Eli Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
ES2542753T3 (es) 2008-04-28 2015-08-10 Kyorin Pharmaceutical Co., Ltd. Derivado de ciclopentilacrilamida
EP3199623B1 (en) 2010-03-31 2021-07-28 The Scripps Research Institute Reprogramming cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
TR199902442T2 (xx) * 1997-01-28 2000-07-21 Merck & Co.,Inc. �eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler.
SI1169312T1 (en) * 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918363B (zh) * 2008-01-18 2012-09-05 安斯泰来制药株式会社 苯乙酰胺衍生物

Also Published As

Publication number Publication date
DE60111540D1 (de) 2005-07-21
DE60111540T2 (de) 2006-03-16
US20020065275A1 (en) 2002-05-30
AU8399801A (en) 2002-02-25
PT1311504E (pt) 2005-10-31
CN1466584A (zh) 2004-01-07
DK1311504T3 (da) 2005-10-17
CA2419416C (en) 2009-10-13
US20020035266A1 (en) 2002-03-21
CA2419416A1 (en) 2002-02-21
PE20020386A1 (es) 2002-05-13
ATE297921T1 (de) 2005-07-15
JP2004506632A (ja) 2004-03-04
AR031718A1 (es) 2003-10-01
BR0113312A (pt) 2003-07-01
ES2243541T3 (es) 2005-12-01
US6369232B1 (en) 2002-04-09
AU2001283998B2 (en) 2005-10-20
KR100518061B1 (ko) 2005-09-28
MXPA03001275A (es) 2003-06-30
EP1311504A1 (en) 2003-05-21
ZA200300904B (en) 2004-04-30
CN1209362C (zh) 2005-07-06
US6441180B1 (en) 2002-08-27
US6388088B1 (en) 2002-05-14
KR20030022408A (ko) 2003-03-15
UY26885A1 (es) 2002-02-28
EP1311504B1 (en) 2005-06-15
PA8525201A1 (es) 2002-07-30
US20020035267A1 (en) 2002-03-21
WO2002014312A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
JP3961948B2 (ja) テトラゾリル−フェニルアセトアミドであるグルコキナーゼ活性化物質
AU2001283998A1 (en) Tetrazolyl-phenyl acetamide glucokinase activators
JP3824936B2 (ja) ｔｒａｎｓオレフィン系グルコキナーゼアクチベーター
JP3971189B2 (ja) ｐ−アミノ置換フェニルアミドグルコキナーゼ活性化物質
JP4138478B2 (ja) アルファ−アシル及びアルファ−ヘテロ原子置換ベンゼンアセトアミドのグルコキナーゼアクチベーター
JP4091600B2 (ja) 置換フェニルアセトアミド及びグルコキナーゼ活性化物質としてのその使用
KR100545431B1 (ko) 축합된 이종방향족 글루코키나제 활성화제
MXPA02010745A (es) Activadores de glucocinasa heteroaromaticos de alquinil-fenilo.
JP2002540196A (ja) グルコキナーゼ活性化物質

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070517

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110525

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120525

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees